Amyndas features in BioWorld, the biopharmaceuticals news source from Thomson Reuters

Amyndas’ recent developments caught the interest of the international press, with BioWorld publishing an article about Amyndas on July 17. In this article, Amyndas is presented as an emerging company aiming to create novel therapeutics to treat complement-mediated disorders, that could be more potent than other complement inhibitors. The article is titled “Two- pronged Amyndas targets complement-based anti-inflammatories.”

To read article: